Ginkgo Bioworks Holdings (DNA) Non Operating Investment Income (2020 - 2026)
Ginkgo Bioworks Holdings' (DNA) quarterly Non Operating Investment Income came in at -$1.2 million in Q1 2026, up 67.13% YoY from -$726393.7 in Q1 2025, and up 92.49% on a QoQ basis from -$16.2 million in Q4 2025.
Analysis
Ginkgo Bioworks Holdings (DNA) Non Operating Investment Income (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings (DNA) has 7 years of Non Operating Investment Income data on file, last reported at -$1.2 million in Q1 2026.
- Quarterly Non Operating Investment Income rose 67.13% year-over-year to -$1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$13.9 million (up 53.52% YoY) and the FY2025 annual result came in at -$16.4 million, up 43.07% from the prior year.
- Non Operating Investment Income climbed to -$1.2 million in Q1 2026, from -$16.2 million in the prior quarter.
- In the past five years, Non Operating Investment Income ranged from a high of $3.7 million in Q3 2025 to a low of -$38.7 million in Q2 2022.
- A 5-year average of -$9.1 million and a median of -$6.4 million in 2023 frame the typical range for Non Operating Investment Income.
- Annual changes were most pronounced in 2023 — Non Operating Investment Income tumbled 1966.21% — and 2025, when it jumped 153.3%.
- Tracing DNA's Non Operating Investment Income over 5 years: stood at -$13.4 million in 2022, then climbed by 25.03% to -$10.0 million in 2023, then dropped by 25.3% to -$12.5 million in 2024, then retreated by 28.92% to -$16.2 million in 2025, then surged by 92.49% to -$1.2 million in 2026.
- The last three Non Operating Investment Income figures came in at -$1.2 million (Q1 2026), -$16.2 million (Q4 2025), and $3.7 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.21 Bn | 132.36 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.04 Bn | 78.05 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.73 Bn | 58.55 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.59 Bn | 52.46 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | - |
| 6 | BeOne Medicines | 40.13 Bn | 35.04 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.55 Bn | 32.24 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.60 Bn | 27.77 Bn | - | - |
| 9 | Insmed | 27.70 Bn | 26.54 Bn | 358.27 Mn | - |
| 10 | Ginkgo Bioworks Holdings | 430.31 Mn | 345.78 Mn | 18.44 Mn | 1.99 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.99 Mn |
| Mar 31, 2026 | -1.21 Mn |
| Dec 31, 2025 | -16.17 Mn |
| Sep 30, 2025 | 3.68 Mn |
| Jun 30, 2025 | -229,000.00 |
| Mar 31, 2025 | -3.69 Mn |
| Dec 31, 2024 | -12.55 Mn |
| Sep 30, 2024 | -6.91 Mn |
| Jun 30, 2024 | -6.83 Mn |
| Mar 31, 2024 | -2.54 Mn |
| Dec 31, 2023 | -10.01 Mn |
| Sep 30, 2023 | -36.32 Mn |
| Jun 30, 2023 | -2.12 Mn |
| Mar 31, 2023 | -6.37 Mn |
| Dec 31, 2022 | -13.35 Mn |
| Sep 30, 2022 | -1.76 Mn |
| Jun 30, 2022 | -38.67 Mn |
| Mar 31, 2022 | 450,000.00 |
| Dec 31, 2021 | -14.55 Mn |
| Sep 30, 2021 | -12.37 Mn |